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 Introduction:
• Hsp90 (Heat shock protein 90) a well-conserved protein 
• Involved in the proper refolding of proteins 
• located in the cytosol as Hsp90α and β 
• Possesses isoforms in mitochondria (hsp75,TRAP-1) 
• endoplasmic reticulum (grp94) 
• can repaire Almost 400 proteins         some of which facilitating the oncogenic process 
• Targeting hsp90 promising strategy
• Hsp90 is part of a complex machinery
• works together with hsp70, hsp40 
• consists of three domains:
• N-terminal domain involved in ATP hydrolysis
• intermediate domain with high affinity for client proteins 
• C-terminal domain responsible for dimerization 
• N-terminal inhibitors such as geldanamycin promising results in solid tumors 
• side effects and poor tolerance to the treatment
• induce an overexpression of hsp70       HSR
• constant efforts to synthesize more efficient compounds 
• higher clinical tolerability and that do not induceca HSR 
• Among the nvb derivatives        6BrCaQ
• promising results in MCF-7 cells 
• anti-proliferative effects in vitro 
• client protein degradation 
• very insoluble in aqueous media 
• Our strategy use nanoparticulate carriers 
• overcome solubility problems and improve bioavailability 
• also to specifically deliver them 
• In a previous study        encapsulated 6BrCaQ in PEGylated liposomes in the 
PC-3 prostate cancer cell line
• pro-apoptotic effects, a G2/M cell cycle blockade and a synergistic effect with 
doxorubicin
• liposomal 6BrCaQ retarded cell migration
• PEGylated liposomes can take advantage        enhanced permeation and 
retention effect (EPR) 
• higher permeability of tumor blood vessels
• reduced lymphatic drainage 
• resulting in a better accumulation at the cancer site
 Material and methods
Chemicals:
• 6BrCaQ 
The pure compound was solubilized at 10mM in chloroform for liposome 
preparation and in DMSO for use as a free drug. 
• Egg chicken L-α- phosphatidylcholine (Egg PC) 
• Cholesterol (CH) 
• DSPE-PEG2000
• Rho-PE
Stock solutions of lipids (25 mg/ml for each) were made in chloroform.
Cell lines and culture:
• MDA-MB-231 cells, either wild type or expressing GFP and firefly luciferase 
(Luc2-GFP) 
• negative for Mycoplasma Mycoalert™ detection kit 
• MDA-MB-231 wild type        L15 medium supplemented with 15% heat-
inactivated fetal bovine serum, 2mM glutamine, 22mM NaHCO3 and 0.5% of 
Penicillin-Streptomycin
• MDA-MB-231 Luc2-GFP EMEM supplemented with 10% heat-
inactivated fetal bovine serum, 2mM glutamine and 0.5% of Penicillin-
Streptomycin
• were incubated in a humidified atmosphere containing 5% CO2 at 37 °C
Liposome preparation:
• composed of Egg PC, Cholesterol and DSPE-PEG2000 (2.17:1:0.17 
respectively molar ratio) 
• were formed         by the thin film hydration method 
• mixture was dried        at 25 °C using a rotary evaporator for 60 min 
• film was hydrated a sterile-filtered buffer solution 
• (10mM HEPES,145mM NaCl, pH=7.4) at room temperature 
• The multilamellar liposomes formed were sequentially extruded 
through polycarbonate membranes
• 6BrCaQ was added in excess an optimal drug-to-lipid ratio 
could be reached
• The extrusion process was able to remove most of the non-
incorporated 6BrCaQ, which remained on the membrane after 
extrusion
• Rhodamine-PE (1% mol) replacing 1% mol of Egg PC in 
chloroform mixture For in-vitro uptake experiments 
Determination of encapsulation efficiency and drug-to-lipid 
ratio in the liposomes:
• to remove non-encapsulated drug         low-speed centrifugation (10 min; 
10,000 g)
• to determine the liposome-associated drug in the supernatant 
• fluorescence assay (λexcitation=340 nm; λemission=390 nm)
• Lipids did not interfere with the fluorescence of 6BrCaQ at the wavelengths 
used
• To assess lipid recovery, the PC content was assayed an enzymatic 
colorimetric kit
• calculation the total lipid concentration 
• assuming that the proportions remained constant
• Encapsulation efficiency (EE%) 
• drug loading (D/L%)
Size and zeta potential measurements:
• The mean hydrodynamic diameter of the liposomes  
Determined by Dynamic Light Scattering 
• Samples were diluted in pure water prior to the measurements 
• analysed at a backscatter angle of 173°
• Polydispersity index (PDI) was used as an indicator of size distribution.
• Zeta potential was measured in a folded capillary cell after 30-fold dilution 
in pure water
Cell cycle analysis:
• MDA-MB-231 cells were seeded for 24 h in a 6-well plate (105/well)
• treated with 10 μM of liposomal 6BrCaQ or empty liposomes for 24 h
• Thereafter cells were washed in PBS, recovered in a sufficient number
(2× 105 cells) and permeabilized in ethanol 70% (−20 °C)
• On the day of analysis centrifugation 
• staining by a PBS solution containing DNAse free ribonuclease A (100 μg/mL) 
and propidium iodide (PI) (12.5 μg/mL)
• Data were then acquired with a flow cytometer and the 
• cell cycle was analysed FlowJo software
Cell viability determination (MTS assay and trypan blue staining):
• Cell viability was determined the Cell Proliferation Assay (Promega)
• MDA-MB-231 (5000 cells/well) were seeded into 96-well plates
• treated with loaded liposomes, free drug and vehicle controls for 24 h
• Each culture condition was analysed in 5 wells for each plate and the 
experiment was repeated three times.
• Absorbance values at 492 nm
• The absorbance recorded with non-treated cells was taken as 100% 
of metabolic activity corresponding to maximum viability. 
• Cell viability and proliferation were determined after 24 h treatment 
by Trypan blue exclusion
• Each sample was diluted with Trypan blue       1:1 ratio
• Viable and dead cells were then counted by optical microscopy
Real-time cell analysis (xCELLigence technology):
• The biological activity of liposomes containing 6BrCaQ was assessed 
• with the Real-Time Cell Analyzer multi-plate (RTCA MP) Instrument
• using the xCELLigence System 
• 5×103 MDA-MB-231 cells/per well         were plated in an E-Plate View 96
• placed in the RTCA MP located inside a cell culture incubator 
• left to grow for 24 h before treatment 
• impedance was continuously measured until the end of the treatment
• Standard deviations of well replicates were analysed with the RTCA Software
Confocal microscopy:
• Cells were seeded in Lab-Tek 8-well plates
• After 24 h, culture medium was replaced 
• medium containing liposomes incorporating a rhodamine-labelled phospholipid
(1% molar ratio)
• cells were incubated up to 4 h with liposomes at 37 °C (1.6×104 cells)
• then washing with cold PBS 
• followed by fixation in paraformaldehyde (2%)
• The association of liposomes with the cells 
was observed by confocal microscopy
http://microscopy.wfu.edu/instrumentation/confocal-microscope/
Western blots:
• Frozen cell pellets were lysed in RIPA buffer containing phosphatase and 
protease inhibitors for 30 min on ice
• Protein concentrations in lysates were assayed using Biorad protein assay 
(Bradford method)
• SDS-PAGE (4–15% or 4–20% acrylamide to obtain a good resolution of 
the protein profile) (150–200 V for about one hour)
• Proteins were transferred to a PVDF membrane (100 V 45 min) (liquid 
transfer) 
• the quality of the transfer was checked by Ponceau Red staining. 
• For immunodetection membranes were saturated in 5% non-fat milk 
TBS- Tween 0.1% for one hour at room temperature 
• incubated with primary antibody dilutions overnight (4 °C) 
• anti-Hsp70, anti-Hsp90α/β, anti-CDK-4, anti-PARP-1, and anti-GAPDH 
• After washing, horse-radish peroxidasecoupled secondary antibodies 
(anti-mouse) were added for 1 h 
• Chemiluminescent signals were analysed using the MF ChemiBis system
• densitometry analysis was performed using MultiGauge Software.
Real time RT-PCR:
• At the end of the treatment        cells are collected and pellets 
• Were washed twice with sterile PBS and kept dry at −80 °C freezer
• Total cellular RNA was isolated using RNeasy Mini Kit columns
• RNA quantification measuring the absorbance at 260 nm
• 2 μL of each sample are used to measure 
• absorbances at 230–260 – 270–280 and 320
• Samples of a RIN index lower than 8.0 were discarded
• 400 ng aliquot of total RNA was retrotranscribed using the iScript™ cDNA 
Synthesis Kit 
• After dilution, 3 ng of cDNA was then subjected to real-time PCR analysis 
• using the SYBR Green 
• following specific primers systems 
• Specific amplification of the gene of interest was checked by analysis of 
melting curves 
In-vivo orthotopic breast cancer model:
• on 4-6 weeks-old female nude mice (Fox1nu,nu/nu) 
• Cultured MDA-MB-231-Luc2-GFP cells 
• recovered using trypsin, centrifuged (300 g; 5 min) and washed 
three times in PBS
• Cells were then injected to the mammary fat pad of mice 
(500,000 cells in 50 μL of PBS) one week after animal arrival
• Mice were then checked every day for recovery
• No differences in terms of weight were observed between mice 
receiving surgery and untreated mice
• Bioluminescence was monitored weekly 
• D-luciferin (150 mg/kg) was injected intraperitoneally
• Bioluminescence (photons/sec) was then acquired 6 min after injection
• Obtained images were analysed the Living Image Software
• Initiatation of treatment        tumors reached a size of 60mm3 3–4 weeks after 
tumor implantation
• liposomes injected into the tail vein once a week until the end of the 
experiment (34 days after treatment Initiation)
Histology:
• Tumors were recovered from mice on euthanasia 34 days after 
the beginning of treatment
• mice had received 5 injections
• fixed in a 4% formaldehyde solution overnight at 4 °C
• Then, washing three times in PBS 
• preserving in ethanol 70 °C before inclusion in paraffin 
• hematoxylin and eosin Staining 
• Slides were scanned and analysed with Imagescope software
Immunohistochemical analysis:
• using a Ventana Discovery XT autostainer on 4 μm-thick paraffin sections
• Slides deparaffinizing with EZPrep buffer 
• epitopes were unmasked by 15 min high-temperature treatment in CC1 EDTA 
buffer
• Sections were incubated 40 min at room temperature with anti-Ki67 antibody 
or cleaved caspase 3 antibody 
• Secondary antibody was incubated 16 min at room temperature
• After washes, staining was performed with DAB
• sections were counterstained with Hematoxylin using Ventana reagents 
Image analysis:
• The proportion of necrotic area Aperio Imagescope software
• Analyses of proliferation        Ki67 staining
• apoptosis        cleaved-caspase 3 staining
• using 6 randomly chosen fields selected on each histological section 
• Ki67 and cleaved-caspase 3-positive cells countting Image J software
Statistical significance:
• All data were expressed as mean ± SEM
• checking Gaussian distribution
• differences between experimental groups 
• ANOVA and student's t-test
• Data were considered statistically significant : p < 0.05
• Two independent experiments 
• the results were pooled
• After checking Gaussian distribution, aberrant values were removed
Characterization of liposomes:
• Empty liposomes         a mean diameter of 124 nm 
• loaded liposomes        a similar diameter of around 121 nm 
• Both preparations had a PDI<0.2 monodisperse distributions 
• Both showed similar surface charge (both around −13 mV)
 Results
Anti-proliferative and cytotoxic effects in vitro:
• rhodamine-labelled liposomes could be seen within the cells after 4 h 
• The metabolic activity of MDA-MB-231 cells:
• around 35% for liposomal 6BrCaQ against 81% for the free drug with MTS assay 
• checking the effect on proliferation         trypan blue staining,after 24 h:
• A slight but significant effect on cell viability between loaded and empty liposomes 
(92% and 75% respectively)
• a more significant and important effect on the number of cells remaining after a 
treatment of 24 h (7×105 for empty liposomes against 2× 105 for loaded 
liposomes)

• confocal microscopy image of MDA-MB-231 cells after 4 h incubation with 
rhodamine-labelled liposomes loaded with 6BrCaQ (10 μM) (scale bar=10 μm)
• XCELLigence experiments        checking the effect on proliferation 
or cytotoxicity 
• cell growth was decreased upon treatment 
• with 3 μM liposomal 6BrCaQ as compared with empty liposomes 
and untreated cells

• Flow cytometry experiments on MDA-MB-231 cells 
• treated with free and liposomal 6BrCaQ (10 μM; 24 h) 
• to determine the distribution in each cell cycle phase
• around 46% of cells in the S phase after treatment with loaded 
liposomes 
• around 25% of cells in this phase with controls and free 6BrCaQ
• Liposomal 6BrCaQ induced a S/G2/M arrest 
• the free 6BrCaQ blocked in G2/M phase

Western blots:
• western blots To understand the impact of liposomal 6BrCaQ on 
chaperone expression 
• The expression of hsp70 and hsp90 slightly and significantly 
decreased
• after treatment with 10 μM liposomal 6BrCaQ, 24 h
• The same trend was observed with the client protein CDK-4

Gene expression for several chaperone proteins after treatment with
liposomal 6BrCaQ:
• gene expression coding        quantitative RT-PCR experiments 
• several chaperone proteins possibly involved in the induction of HSR
• on MDA-MB-231 cells treated 
• 10 μM liposomal 6BrCaQ for 24 h and 48 h 
• MDA-MB-231-luc2 (data not shown)
• No significant changes were observed for hsp90α, hsp90β, hsp70 and hsp27

In-vivo anti-tumor efficacy:
• To study the effect of liposomal 6BrCaQ on tumor growth in vivo
• An orthotopic breast cancer model 
• Female nude mice       were injected with 5× 105 MDA-MB-231 luc/GFP cells
• Tumors were observable 3–4 weeks after surgery 
• Tumor growth was followed by bioluminescence
• no change of behavior or weight were observed        as mice still fed correctly

• Bioluminescence measurements revealed a stabilization of the signal 
• with loaded liposomes (2–3 fold increased) 
• control group showed increasing signal (up to 7-fold at day 28)
• relative tumor volume on the day of euthanasiathe
• be increased 6-fold in the treated group 
• 13-fold in control group


• the proportion of necrotic areas between treated and control groups:
• A significant increase was observed after treatment with loaded liposomes 
• around 28% necrosis in the treated group 
• 11% in control group 
• The proportion of ki67 positive cells: 
• slightly decreased in the treated group (64% against 48% in the control group) 
• in caspase 3 cleavage:
• no difference between control and treated groups 




• The aim of our work        characterize the anti-tumor potential of 6BrCaQ, 
encapsulated in PEGylated liposomes in a breast cancer model in vivo
• This type of liposome is frequently used for drug delivery of anticancer agents 
• they show reduced liver and spleen accumulation 
• prolonged residence time in the blood due to the presence of PEG
• Firstly, the anti-proliferative and pro-apoptotic effects of liposomal
• 6BrCaQ were verified in vitro on MDA-MB-231 cells
• more effective towards MDA-MB-231 compare with free drug 
• better apparent solubility 
• free 6BrCaQ    create needle-shaped crystals in the culture medium 
• Loaded liposomes enhanced inhibitory effect on metabolic activity 
• revealed by a lower IC50 compared with free 6BrCaQ 
• trypan blue-staining       To verify whether decreased metabolic activity could be 
attributed: to cytotoxicity or to an inhibition of cell proliferation
• no cleavage of PARP was observed by western blot experiments (data not shown)
• meaning that no apoptosis occurred after treatment with 10 μM liposomal 
6BrCaQ for 24 h
• induction of cell cycle blockade in S/G2/M phase
• loaded liposomes inhibit proliferation more than they induce cell mortality
• To go further in the characterization of the cell response 
• real-time cell analysis using xCELLigence technology 
• The data confirm trypan blue exclusion and cell cycle analysis
• For all these experiments, no effects on cell were observed with empty liposomes
• A major issue for hsp90i HSR induction 
• can lead to the development of resistance to treatment 
• failure in clinical trials 
• Liposomal 6BrCaQ does not induce a HSR
• (by checking the expression of chaperone proteins and their genes)
• At the protein level, hsp90 is decreased
• probably through degradation 
• since its gene expression is not affected by treatment 
• CDK-4 was slightly reduced after treatment
• interaction drug with hsp90         induce client protein degradation
• The ability to decrease cell proliferation in vitro 
• was confirmed in vivo in nude mice
• After weekly injections of 1 mg/kg liposomal 6BrCaQ
• stabilization of tumor growth 
• measured by relative luc2 bioluminescence
• No changes in behavior of mice and no variations of weight
• tumors were measured         a significant decrease in volume in the treated group
• Histological examination (34 days after beginning treatment) 
• with H&E staining
• histological sections        analysed for Ki67 expression 
• To understand the tumor volume stabilization in treated mice,
• a slight but significant decrease in the number of Ki67-positive cells in 
the treated Group
• the important proportion of necrotic areas in treated mice 
• an effect of drug-loaded liposomes on the tumor vasculature 
• causing hypoxia
• not because of apoptosis induction
• necrotic areas were also observed in control group
• necrotic process could also be correlated with tumor growth
 Conclusion
• on breast cancer models, liposomes encapsulating 6BrCaQ:
• exert significant anti-proliferative effects in vitro
• cell cycle arrest in the S-G2/M phase 
• tumor growth stabilization observed by luciferase bioluminescence in vivo 
• histological observations revealed a significant decrease in the number of 
proliferative cells 
• increased necrotic areas in treated mice
• no apoptosis induction were observed through caspase 3 cleavage 
• No direct toxicity was observed in mice injected with 1 mg/kg liposomal 
6BrCaQ once a week for 4 weeks
• This formulation represents a promising alternative for breast cancer therapy
• associate liposomal 6BrCaQ with a cytotoxic anti-cancer agent 
• take advantage of these anti-proliferative effects 
• to sensitize tumors to other anti-neoplastic agents 
• Another strategy       combine this drug with a hsp70 inhibitor 
• further impact the HSR

